Melinta Therapeutics Inc., a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, will acquire the infectious disease business from The Medicines Company for $165 million plus shares of its stock.
The acquisition includes three marketed products: recently approved and launched vaborbactam-meropenem (Vabomere), and established commercial products oritavancin (Orbactiv) and minocycline (Minocin IV).
The deal was unanimously approved